Literature DB >> 7426837

Direct vasodilatation by labetalol in anaesthetized dogs.

R C Dage, C P Hsieh.   

Abstract

1 The effects of several doses of labetalol (0.03 to 1 mg/kg) given intravenously and into the vertebral artery were examined in anaesthetized dogs. Labetalol produced to immediate (5 min) change in blood pressure or heart rate when given by either route, with one exception. Heart rate increased after the first dose (0.03 mg/kg i.v.) of labetalol. By contrast, clonidine (1 micrograms/kg) elicited an immediate and prolonged fall in blood pressure and heart rate when given into the vertebral artery, but not intravenously. 2 In the isolated perfused gracilis muscle of the dog, following alpha- and beta-adrenoceptor blockade, intra-arterial injections of labetalol (0.3 to 10 mg) or diazoxide (0.3 to 1 mg) produced decreases in perfusion pressure that were dose-related in both magnitude and duration. The doses of labetalol and diazoxide required to produce a half-maximal vasodilatation were 1.5 mg and 0.7 mg respectively. 3 In adrenalectomized, vagotomized spinal dogs, both labetalol (0.1 to 1 mg/kg i.v.) and hydralazine (1 mg/kg i.v.) elicited a fall in blood pressure without changing heart rate or cardiac output. 4. These results suggest that the hypotension produced by systemically administered labetalol does not involve an action in the brain. It may involve instead a direct vasodilatation of resistance blood vessels, since labetalol in sufficient amounts, directly dilates resistance vessels and lowers blood pressure in dogs devoid of adrenergic tone. Direct vasodilatation may be a component of the hypotensive action of labetalol.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7426837      PMCID: PMC2044336          DOI: 10.1111/j.1476-5381.1980.tb07934.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  20 in total

1.  Autonomic regulation of arterial pressure responses.

Authors:  I H Page; J W McCubbin
Journal:  Arch Int Pharmacodyn Ther       Date:  1965-09

2.  Pressor action of beta blocking agents in rats.

Authors:  D Regoli
Journal:  Can J Physiol Pharmacol       Date:  1970-07       Impact factor: 2.273

3.  Analysis of the cardiovascular effects of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (Catapres).

Authors:  J W Constantine; W K McShane
Journal:  Eur J Pharmacol       Date:  1968-09       Impact factor: 4.432

4.  Acute hypotensive action of 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155) after infusion into the cat's vertebral artery.

Authors:  R W Sattler; P A van Zwieten
Journal:  Eur J Pharmacol       Date:  1967-10       Impact factor: 4.432

5.  Clinical investigation of an antagonist at alpha- and beta-adrenoceptors-AH5158A.

Authors:  J G Collier; N A Dawnay; C Nachev; B F Robinson
Journal:  Br J Pharmacol       Date:  1972-02       Impact factor: 8.739

6.  Hemodynamic changes in dogs caused by sodium pentobarbital anesthesia.

Authors:  F Olmsted; I H Page
Journal:  Am J Physiol       Date:  1966-04

7.  Haemodynamic effects of combined alpha- and beta-adrenoreceptor blockade after intravenous labetalol in hypertensive patients at rest and during exercise.

Authors:  G Koch
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

8.  Haemodynamic effects of long-term oral labetalol.

Authors:  R C Edwards; E B Raftery
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

9.  Pharmacology of AH 5158; a drug which blocks both - and -adrenoceptors.

Authors:  J B Farmer; I Kennedy; G P Levy; R J Marshall
Journal:  Br J Pharmacol       Date:  1972-08       Impact factor: 8.739

10.  Metabolism of labetalol by animals and man.

Authors:  L E Martin; R Hopkins; R Bland
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

View more
  10 in total

Review 1.  Properties of labetalol, a combined alpha- and beta-blocking agent, relevant to the treatment of myocardial ischemia.

Authors:  W H Frishman
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

2.  Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats.

Authors:  H Hashimoto; M Tanaka; A Kanda; A Akashi
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Labetolol in patients with hypertension and varying degrees of renal impairment.

Authors:  E G Breen; M Lombard; A Watson; J A Keogh
Journal:  Ir J Med Sci       Date:  1984-10       Impact factor: 1.568

4.  Propranolol versus labetalol: interesting differences in efficacy.

Authors:  W Flamenbaum
Journal:  J Natl Med Assoc       Date:  1985-05       Impact factor: 1.798

5.  Antiarrhythmic efficacy of labetalol as assessed by programmed electrical stimulation.

Authors:  G Krumpl; H Todt; K Krejcy; G Raberger
Journal:  Br J Pharmacol       Date:  1990-08       Impact factor: 8.739

Review 6.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 7.  Role of vasodilation in the antihypertensive and antianginal effects of labetalol: implications for therapy of combined hypertension and angina.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1988-09       Impact factor: 3.727

8.  Effect of labetalol on limb haemodynamics in patients following coronary artery bypass graft surgery.

Authors:  J L Halperin; B P Mindich; E B Rothlauf; R F Reder; R S Litwak; J Kupersmith
Journal:  Br J Clin Pharmacol       Date:  1986-05       Impact factor: 4.335

9.  Retrospective evaluation of labetalol as antihypertensive agent in dogs.

Authors:  Francesco Zublena; Chiara De Gennaro; Federico Corletto
Journal:  BMC Vet Res       Date:  2020-07-24       Impact factor: 2.741

10.  Sevoflurane with opioid or dexmedetomidine infusions in dogs undergoing intracranial surgery: a retrospective observational study.

Authors:  Felipe Marquez-Grados; Enzo Vettorato; Federico Corletto
Journal:  J Vet Sci       Date:  2020-01       Impact factor: 1.672

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.